Skip to content

Ketamine research published in 2023

Page 12 of 18: studies 221 to 240 of 355, newest first. Back to the ketamine overview

Studies

Oral and Intranasal Ketamine Use in Treatment-Resistant Catatonia: A Clinical Case Report.

The American journal of case reports April 25, 2023 Elizabeth A Gregor, Wanhong Zheng

BACKGROUND Benzodiazepines and electroconvulsive therapy (ECT) are standard treatment options for catatonia, a life-threatening psychomotor syndrome in people with serious mental illness. The purpose of this study was to discuss the use of ketamine in treatment-resistant catatonia, which has not been established in current literature. CASE REPORT A 63-year-old woman with schizoaffective...

Ketamine abuse: Another side of the miracle drug (A case report)

Journal of Clinical Case Reports Medical Images and Health Sciences April 21, 2023 Bouchra Hallab

Ketamine is a " dissociative anaesthetic " with fast analgesic and amnesic properties that has been used since more than 40 years. Today, ketamine abuse has become a public health concern. We report the case of a 23-year-old patient who came to the Casablanca Addictology Centre asking for help with ketamine abuse. At the interview the patient presented depressive symptoms and had already made 3...

Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.

Pharmaceuticals April 21, 2023 Thi Mai Loan Nguyen, Fabrice Jollant, Laurent Tritschler et al.

Around 700,000 people die from suicide each year in the world. Approximately 90% of suicides have a history of mental illness, and more than two-thirds occur during a major depressive episode. Specific therapeutic options to manage the suicidal crisis are limited and measures to prevent acting out also remain limited. Drugs shown to reduce the risk of suicide (antidepressants, lithium, or...

Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial

Neuropsychopharmacology April 19, 2023 N. Murphy, Amanda J. F. Tamman, Marijn Lijffijt et al. 18 citations

Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects,...

Sex and Estrous Cycle Are Not Mediators of S-Ketamine’s Rapid-Antidepressant Behavioral Effects in a Genetic Rat Model of Depression

The International Journal of Neuropsychopharmacology April 17, 2023 Shokouh Arjmand, Marie Vadstrup Pedersen, N. Silva et al.

Abstract Background Recent preclinical and clinical studies have shed light on the possible impact of sex and estrous/menstrual cycle on ketamine’s antidepressant action but with incongruous results. The preclinical studies that have shown the effects of ovarian sex hormones have not done so in animal models of depression. Thus, the aim of the present study is to scrutinize the acute behavioral...

Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system

bioRxiv Preprint Server April 12, 2023 Malika S. Datta, Yannan Chen, Shradha Chauhan et al. 6 citations preprint

Ketamine is a multifunctional drug with clinical applications as an anesthetic, as a pain management medication and as a transformative fast-acting antidepressant. It is also abused as a recreational drug due to its dissociative property. Recent studies in rodents are revealing the neuronal mechanisms that mediate the complex actions of ketamine, however, its long-term impact due to prolonged...

A Multifunctional Nanocarrier System for Highly Efficient and Targeted Delivery of Ketamine to NMDAR Sites for Improved Treatment of Depression

Advanced Healthcare Materials April 8, 2023 Jing Ge, Ronghua Tan, Qian Gao et al.

Ketamine (KA), commonly used as an anesthetic, is now widely studied as an antidepressant for the treatment of depression. However, due to its side effects, such as addiction and cognitive impairment, the dosage and frequency of (S)‐ketamine approved by the FDA for the treatment of refractory depression is very low, which limits its efficacy. Here, a new multifunctional nanocarrier system...

COMBINATION OF INTRAVENOUS KETAMINE AND ELECTROCONVULSOTHERAPY FOR TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW

International Journal of Health Sciences April 5, 2023 Luísa Soares Capa, Gabrielle Simon Tronco, Virginia Nascimento Reinert et al.

: Treatment-resistant depression is a common psychiatric disorder that can lead to significant disability and decreased quality of life for patients. In recent years, there has been growing interest in the combination of intravenous ketamine and electroconvulsive therapy (ECT) for the treatment of treatment-resistant depression. Ketamine is an anesthetic that is an N-methyl-D-aspartate (NMDA)...

Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression: A Patient With Lifelong Self-Doubt and Self-Criticism.

The Journal of Clinical Psychiatry April 5, 2023 Albert Yeung, Guy Sapirstein, Laura D Crain et al.

Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...

One binge-type cycle of alcohol plus ketamine exposure induces emotional-like disorders associated with oxidative damage in adolescent female rats.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie April 4, 2023 C. C. M. D. Menezes da Silveira, Sabrina de Carvalho Cartágenes, Natália Harumi Correa Kobayashi et al.

Drug abuse is a global public health problem among adolescents, with alcohol often used in association with other psychotropic drugs, such as ketamine. Considering the scarcity of evidence, this study aimed to investigate emotional behavioral effects induced by ethanol plus ketamine co-abuse, as well as oxidative biochemistry, and neurotrophic mediator in the prefrontal cortex and hippocampus...

Activation of ventral hippocampal CB1 receptors inhibits ketamine-induced anxiogenic-like behavior: Alteration of BDNF/c-Fos levels in the mouse hippocampus.

Brain Research April 1, 2023 Sakineh Alijanpour, Ameneh Rezayof

Considering the increasing usage of ketamine as a recreational drug with hallucinogenic properties and also scarce studies about receptor systems responsible for its effects, in the present study we aimed to investigate whether the activation of the ventral hippocampal (VH) CB1 cannabinoid receptors affects the anxiety-like behaviors induced by ketamine. Also, the levels of BDNF and c-Fos...

The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia.

Australasian Psychiatry April 2023 William Lugg

To review the sequence of events that led to the Therapeutic Goods Administration (TGA) approval of esketamine in Australia, and to explore the potential ethical and clinical consequences of it. Trust in the TGA is of paramount importance to Australian psychiatrists. The approval of esketamine raises serious questions about the processes, independence and authority of the TGA, and therefore the...

A Comparison of the Anti-Anxiety Effects of Oral Ketamine and Fluvoxamine in Children with Separation Anxiety Disorder Manifesting as School Refusal

Advanced Biomedical Research April 1, 2023 Afsaneh Karbasi Amel, Farzaneh Hosseini 5 citations

Background: Children suffer from a high prevalence of anxiety problems that require prompt treatment. It has been demonstrated that ketamine offers rapid anti-anxiety effects. This study aimed to evaluate ketamine's anti-anxiety impact in the treatment of children with school-refusal separation anxiety disorder. Materials and Methods: In this open-labeled randomized clinical trial, 71 children...

Conditioned anti-immobility by ketamine: A comparison to escitalopram and bupropion.

Experimental and Clinical Psychopharmacology April 1, 2023 Brett Melanson, Michael Wolter, Zion Leatham et al.

This study was designed to explore the clinical belief that "set and setting" play an important role in favorable responses to psychedelic agents such as ketamine (KET). In fact, there is evidence in animals that the antidepressant effect of this drug may involve drug-environment interactions in which a context paired with its effects acquires the ability to influence behavior. Therefore, it...

Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior

Palliative & Supportive Care April 1, 2023 Fernando Espí Forcén, Laura Marengo, Maya Behn

AbstractThere is a current debate in society as to whether depression can be a terminal illness. Meaning-centered psychotherapy (MCP) and psychedelic medicines have both been shown to treat existential distress in palliative care settings. We are reporting the case of a patient for whom MCP combined with ketamine was an effective treatment for his recurrent and severe depressive disorder with...

Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.

Journal of Affective Disorders April 1, 2023 Olivier Payette, Paul Lespérance, V. D. Jodoin et al. 7 citations

BACKGROUND For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure. METHODS...

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Pharmaceuticals April 1, 2023 Aleksander Kwaśny, A. Włodarczyk, Damian Ogonowski et al. 27 citations

Background: Depression is a debilitating disease with a high socioeconomic burden. Regular antidepressants usually require several weeks to ameliorate symptoms; however, numerous patients do not achieve remission. What is more, sleep disturbances are one of the most common residual symptoms. Ketamine is a novel antidepressant with rapid onset of action with a proven antisuicidal effect. Little...

Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.

Journal of Affective Disorders April 1, 2023 Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, Jacqueline Khalil et al. 16 citations

INTRODUCTION Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD). We performed an exploratory investigation of how ketamine treatment in TRD affects different cognitive domains and relates to antidepressant response. METHODS Patients with TRD (N = 66; 30 M/35F; age = 39.5 ± 11.1 years) received four ketamine infusions (0.5 mg/kg). Neurocognitive...

Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.

Psychopharmacology April 1, 2023 David S. Mathai, Sandeep M. Nayak, David B. Yaden et al. 36 citations

The relationship between subjective drug experience and antidepressant outcomes for ketamine derivatives is poorly understood but of high clinical relevance. Esketamine is the patented (S)-enantiomer of ketamine and has regulatory approval for psychiatric applications. We examined the relationship between acute dissociation, as measured by the Clinician-Administered Dissociative States Scale...

Prenatal ketamine exposure impairs prepulse inhibition via arginine vasopressin receptor 1A-mediated GABAergic neuronal dysfunction in the striatum.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie April 1, 2023 Aeseul Kim, Sun Mi Gu, Haemiru Lee et al. 5 citations

Ketamine is a widely used anesthetic with N-methyl-D-aspartate (NMDA) receptor antagonism. Exposure to ketamine and NMDA receptor antagonists may induce psychosis. However, the mechanism underlying the effects of ketamine on the immature brain remains unclear. In this study, NMDA receptor antagonists, ketamine and methoxetamine, were administered to pregnant F344 rats (E17). These regimens...

DOI: 10.1016/j.biopha.2023.114318 (opens in new tab) Full text (opens in new tab) Methoxetamine N-methyl-d-aspartate receptor Prepulse inhibition Δ-aminobutyric acid